Compound 9

Compound 9 is a non-specific designation used in various medicinal chemistry studies to identify the ninth compound in a synthesized series. In the context of opioid research, it refers to a highly potent, non-selective opioid antagonist that targets mu, delta, and kappa opioid receptors. This specific compound has been investigated for its ability to reverse overdoses caused by high-affinity synthetic opioids like carfentanil, which are often resistant to standard doses of naloxone. In other research contexts, Compound 9 has been described as a benzenesulfonamide-based carbonic anhydrase inhibitor for reducing intraocular pressure in glaucoma, as well as various organometallic (gold or platinum-based) and heterocyclic candidates with cytotoxic activity against ovarian and colorectal cancer cell lines.